Efficacy and Safety of Metformin and Atorvastatin Combination Therapy vs. Monotherapy with Either Drug in Type 2 Diabetes Mellitus and Dyslipidemia Patients (ATOMIC): Double-Blinded Randomized Controlled Trial
Background: It is well known that a large number of patients with diabetes also have dyslipidemia, which significantly increases the risk of cardiovascular disease (CVD). This study aimed to evaluate the efficacy and safety of combination drugs consisting of metformin and atorvastatin, widely used a...
Saved in:
| Published in | Diabetes & metabolism journal Vol. 48; no. 4; pp. 730 - 739 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Korea (South)
Korean Diabetes Association / Daehan Dangnyobyeong Hakoe
01.07.2024
Korean Diabetes Association 대한당뇨병학회 |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2233-6079 2233-6087 2233-6087 |
| DOI | 10.4093/dmj.2023.0077 |
Cover
Loading…
| Abstract | Background: It is well known that a large number of patients with diabetes also have dyslipidemia, which significantly increases the risk of cardiovascular disease (CVD). This study aimed to evaluate the efficacy and safety of combination drugs consisting of metformin and atorvastatin, widely used as therapeutic agents for diabetes and dyslipidemia.Methods: This randomized, double-blind, placebo-controlled, parallel-group and phase III multicenter study included adults with glycosylated hemoglobin (HbA1c) levels >7.0% and <10.0%, low-density lipoprotein cholesterol (LDL-C) >100 and <250 mg/dL. One hundred eighty-five eligible subjects were randomized to the combination group (metformin+atorvastatin), metformin group (metformin+atorvastatin placebo), and atorvastatin group (atorvastatin+metformin placebo). The primary efficacy endpoints were the percent changes in HbA1c and LDL-C levels from baseline at the end of the treatment.Results: After 16 weeks of treatment compared to baseline, HbA1c showed a significant difference of 0.94% compared to the atorvastatin group in the combination group (0.35% vs. −0.58%, respectively; P<0.0001), whereas the proportion of patients with increased HbA1c was also 62% and 15%, respectively, showing a significant difference (P<0.001). The combination group also showed a significant decrease in LDL-C levels compared to the metformin group (−55.20% vs. −7.69%, P<0.001) without previously unknown adverse drug events.Conclusion: The addition of atorvastatin to metformin improved HbA1c and LDL-C levels to a significant extent compared to metformin or atorvastatin alone in diabetes and dyslipidemia patients. This study also suggested metformin’s preventive effect on the glucose-elevating potential of atorvastatin in patients with type 2 diabetes mellitus and dyslipidemia, insufficiently controlled with exercise and diet. Metformin and atorvastatin combination might be an effective treatment in reducing the CVD risk in patients with both diabetes and dyslipidemia because of its lowering effect on LDL-C and glucose. |
|---|---|
| AbstractList | Background It is well known that a large number of patients with diabetes also have dyslipidemia, which significantly increases the risk of cardiovascular disease (CVD). This study aimed to evaluate the efficacy and safety of combination drugs consisting of metformin and atorvastatin, widely used as therapeutic agents for diabetes and dyslipidemia.* Methods This randomized, double-blind, placebo-controlled, parallel-group and phase III multicenter study included adults with glycosylated hemoglobin (HbA1c) levels >7.0% and <10.0%, low-density lipoprotein cholesterol (LDL-C) >100 and <250 mg/dL. One hundred eighty-five eligible subjects were randomized to the combination group (metformin+atorvastatin), metformin group (metformin+atorvastatin placebo), and atorvastatin group (atorvastatin+metformin placebo). The primary efficacy endpoints were the percent changes in HbA1c and LDL-C levels from baseline at the end of the treatment.* Results After 16 weeks of treatment compared to baseline, HbA1c showed a significant difference of 0.94% compared to the atorvastatin group in the combination group (0.35% vs. −0.58%, respectively; P<0.0001), whereas the proportion of patients with increased HbA1c was also 62% and 15%, respectively, showing a significant difference (P<0.001). The combination group also showed a significant decrease in LDL-C levels compared to the metformin group (−55.20% vs. −7.69%, P<0.001) without previously unknown adverse drug events.* Conclusion The addition of atorvastatin to metformin improved HbA1c and LDL-C levels to a significant extent compared to metformin or atorvastatin alone in diabetes and dyslipidemia patients. This study also suggested metformin’s preventive effect on the glucose-elevating potential of atorvastatin in patients with type 2 diabetes mellitus and dyslipidemia, insufficiently controlled with exercise and diet. Metformin and atorvastatin combination might be an effective treatment in reducing the CVD risk in patients with both diabetes and dyslipidemia because of its lowering effect on LDL-C and glucose. It is well known that a large number of patients with diabetes also have dyslipidemia, which significantly increases the risk of cardiovascular disease (CVD). This study aimed to evaluate the efficacy and safety of combination drugs consisting of metformin and atorvastatin, widely used as therapeutic agents for diabetes and dyslipidemia. This randomized, double-blind, placebo-controlled, parallel-group and phase III multicenter study included adults with glycosylated hemoglobin (HbA1c) levels >7.0% and <10.0%, low-density lipoprotein cholesterol (LDL-C) >100 and <250 mg/dL. One hundred eighty-five eligible subjects were randomized to the combination group (metformin+atorvastatin), metformin group (metformin+atorvastatin placebo), and atorvastatin group (atorvastatin+metformin placebo). The primary efficacy endpoints were the percent changes in HbA1c and LDL-C levels from baseline at the end of the treatment. After 16 weeks of treatment compared to baseline, HbA1c showed a significant difference of 0.94% compared to the atorvastatin group in the combination group (0.35% vs. -0.58%, respectively; P<0.0001), whereas the proportion of patients with increased HbA1c was also 62% and 15%, respectively, showing a significant difference (P<0.001). The combination group also showed a significant decrease in LDL-C levels compared to the metformin group (-55.20% vs. -7.69%, P<0.001) without previously unknown adverse drug events. The addition of atorvastatin to metformin improved HbA1c and LDL-C levels to a significant extent compared to metformin or atorvastatin alone in diabetes and dyslipidemia patients. This study also suggested metformin's preventive effect on the glucose-elevating potential of atorvastatin in patients with type 2 diabetes mellitus and dyslipidemia, insufficiently controlled with exercise and diet. Metformin and atorvastatin combination might be an effective treatment in reducing the CVD risk in patients with both diabetes and dyslipidemia because of its lowering effect on LDL-C and glucose. Background: It is well known that a large number of patients with diabetes also have dyslipidemia, which significantly increases the risk of cardiovascular disease (CVD). This study aimed to evaluate the efficacy and safety of combination drugs consisting of metformin and atorvastatin, widely used as therapeutic agents for diabetes and dyslipidemia.Methods: This randomized, double-blind, placebo-controlled, parallel-group and phase III multicenter study included adults with glycosylated hemoglobin (HbA1c) levels >7.0% and <10.0%, low-density lipoprotein cholesterol (LDL-C) >100 and <250 mg/dL. One hundred eighty-five eligible subjects were randomized to the combination group (metformin+atorvastatin), metformin group (metformin+atorvastatin placebo), and atorvastatin group (atorvastatin+metformin placebo). The primary efficacy endpoints were the percent changes in HbA1c and LDL-C levels from baseline at the end of the treatment.Results: After 16 weeks of treatment compared to baseline, HbA1c showed a significant difference of 0.94% compared to the atorvastatin group in the combination group (0.35% vs. −0.58%, respectively; P<0.0001), whereas the proportion of patients with increased HbA1c was also 62% and 15%, respectively, showing a significant difference (P<0.001). The combination group also showed a significant decrease in LDL-C levels compared to the metformin group (−55.20% vs. −7.69%, P<0.001) without previously unknown adverse drug events.Conclusion: The addition of atorvastatin to metformin improved HbA1c and LDL-C levels to a significant extent compared to metformin or atorvastatin alone in diabetes and dyslipidemia patients. This study also suggested metformin’s preventive effect on the glucose-elevating potential of atorvastatin in patients with type 2 diabetes mellitus and dyslipidemia, insufficiently controlled with exercise and diet. Metformin and atorvastatin combination might be an effective treatment in reducing the CVD risk in patients with both diabetes and dyslipidemia because of its lowering effect on LDL-C and glucose. KCI Citation Count: 0 It is well known that a large number of patients with diabetes also have dyslipidemia, which significantly increases the risk of cardiovascular disease (CVD). This study aimed to evaluate the efficacy and safety of combination drugs consisting of metformin and atorvastatin, widely used as therapeutic agents for diabetes and dyslipidemia.BACKGRUOUNDIt is well known that a large number of patients with diabetes also have dyslipidemia, which significantly increases the risk of cardiovascular disease (CVD). This study aimed to evaluate the efficacy and safety of combination drugs consisting of metformin and atorvastatin, widely used as therapeutic agents for diabetes and dyslipidemia.This randomized, double-blind, placebo-controlled, parallel-group and phase III multicenter study included adults with glycosylated hemoglobin (HbA1c) levels >7.0% and <10.0%, low-density lipoprotein cholesterol (LDL-C) >100 and <250 mg/dL. One hundred eighty-five eligible subjects were randomized to the combination group (metformin+atorvastatin), metformin group (metformin+atorvastatin placebo), and atorvastatin group (atorvastatin+metformin placebo). The primary efficacy endpoints were the percent changes in HbA1c and LDL-C levels from baseline at the end of the treatment.METHODSThis randomized, double-blind, placebo-controlled, parallel-group and phase III multicenter study included adults with glycosylated hemoglobin (HbA1c) levels >7.0% and <10.0%, low-density lipoprotein cholesterol (LDL-C) >100 and <250 mg/dL. One hundred eighty-five eligible subjects were randomized to the combination group (metformin+atorvastatin), metformin group (metformin+atorvastatin placebo), and atorvastatin group (atorvastatin+metformin placebo). The primary efficacy endpoints were the percent changes in HbA1c and LDL-C levels from baseline at the end of the treatment.After 16 weeks of treatment compared to baseline, HbA1c showed a significant difference of 0.94% compared to the atorvastatin group in the combination group (0.35% vs. -0.58%, respectively; P<0.0001), whereas the proportion of patients with increased HbA1c was also 62% and 15%, respectively, showing a significant difference (P<0.001). The combination group also showed a significant decrease in LDL-C levels compared to the metformin group (-55.20% vs. -7.69%, P<0.001) without previously unknown adverse drug events.RESULTSAfter 16 weeks of treatment compared to baseline, HbA1c showed a significant difference of 0.94% compared to the atorvastatin group in the combination group (0.35% vs. -0.58%, respectively; P<0.0001), whereas the proportion of patients with increased HbA1c was also 62% and 15%, respectively, showing a significant difference (P<0.001). The combination group also showed a significant decrease in LDL-C levels compared to the metformin group (-55.20% vs. -7.69%, P<0.001) without previously unknown adverse drug events.The addition of atorvastatin to metformin improved HbA1c and LDL-C levels to a significant extent compared to metformin or atorvastatin alone in diabetes and dyslipidemia patients. This study also suggested metformin's preventive effect on the glucose-elevating potential of atorvastatin in patients with type 2 diabetes mellitus and dyslipidemia, insufficiently controlled with exercise and diet. Metformin and atorvastatin combination might be an effective treatment in reducing the CVD risk in patients with both diabetes and dyslipidemia because of its lowering effect on LDL-C and glucose.CONCLUSIONThe addition of atorvastatin to metformin improved HbA1c and LDL-C levels to a significant extent compared to metformin or atorvastatin alone in diabetes and dyslipidemia patients. This study also suggested metformin's preventive effect on the glucose-elevating potential of atorvastatin in patients with type 2 diabetes mellitus and dyslipidemia, insufficiently controlled with exercise and diet. Metformin and atorvastatin combination might be an effective treatment in reducing the CVD risk in patients with both diabetes and dyslipidemia because of its lowering effect on LDL-C and glucose. |
| Author | Jeon, Hyun Jeong Kim, Kyung-Soo Kim, Yeo-Joo Lee, Sang Ah Lee, Soon Hee Kim, Dong Joon Kim, Doo-Man Lee, Chang Won Kim, Sung Rae Lim, Soo Kim, Sin Gon Kim, Jung Han Lee, Won-Young Shon, Ho-Sang Kim, Duk Kyu Lee, Seung-Hwan Kim, Sang Wook Kim, In Joo Cho, Sung-Rae Kim, Byung Joon Park, Seok O Park, Keun-Young Seo, Ji A Cho, Chung Gu Lee, Moon-Kyu Kim, Dae Jung Yoo, Jae-Myung Nam-Goong, Il Seong Lee, Jie-Eun Lee, In-Kyu Ahn, Kyu Jeung Kim, Yong-Hyun Min, Kyung Wan Jung, Chang Hee Rhee, Sang Youl Chung, Choon Hee Yu, Seung Hee Song, Kee-Ho |
| Author_xml | – sequence: 1 givenname: Jie-Eun orcidid: 0000-0002-1039-5769 surname: Lee fullname: Lee, Jie-Eun – sequence: 2 givenname: Seung Hee surname: Yu fullname: Yu, Seung Hee – sequence: 3 givenname: Sung Rae surname: Kim fullname: Kim, Sung Rae – sequence: 4 givenname: Kyu Jeung surname: Ahn fullname: Ahn, Kyu Jeung – sequence: 5 givenname: Kee-Ho surname: Song fullname: Song, Kee-Ho – sequence: 6 givenname: In-Kyu surname: Lee fullname: Lee, In-Kyu – sequence: 7 givenname: Ho-Sang surname: Shon fullname: Shon, Ho-Sang – sequence: 8 givenname: In Joo surname: Kim fullname: Kim, In Joo – sequence: 9 givenname: Soo surname: Lim fullname: Lim, Soo – sequence: 10 givenname: Doo-Man surname: Kim fullname: Kim, Doo-Man – sequence: 11 givenname: Choon Hee surname: Chung fullname: Chung, Choon Hee – sequence: 12 givenname: Won-Young surname: Lee fullname: Lee, Won-Young – sequence: 13 givenname: Soon Hee surname: Lee fullname: Lee, Soon Hee – sequence: 14 givenname: Dong Joon surname: Kim fullname: Kim, Dong Joon – sequence: 15 givenname: Sung-Rae surname: Cho fullname: Cho, Sung-Rae – sequence: 16 givenname: Chang Hee surname: Jung fullname: Jung, Chang Hee – sequence: 17 givenname: Hyun Jeong surname: Jeon fullname: Jeon, Hyun Jeong – sequence: 18 givenname: Seung-Hwan surname: Lee fullname: Lee, Seung-Hwan – sequence: 19 givenname: Keun-Young surname: Park fullname: Park, Keun-Young – sequence: 20 givenname: Sang Youl surname: Rhee fullname: Rhee, Sang Youl – sequence: 21 givenname: Sin Gon surname: Kim fullname: Kim, Sin Gon – sequence: 22 givenname: Seok O surname: Park fullname: Park, Seok O – sequence: 23 givenname: Dae Jung surname: Kim fullname: Kim, Dae Jung – sequence: 24 givenname: Byung Joon surname: Kim fullname: Kim, Byung Joon – sequence: 25 givenname: Sang Ah surname: Lee fullname: Lee, Sang Ah – sequence: 26 givenname: Yong-Hyun surname: Kim fullname: Kim, Yong-Hyun – sequence: 27 givenname: Kyung-Soo surname: Kim fullname: Kim, Kyung-Soo – sequence: 28 givenname: Ji A surname: Seo fullname: Seo, Ji A – sequence: 29 givenname: Il Seong surname: Nam-Goong fullname: Nam-Goong, Il Seong – sequence: 30 givenname: Chang Won surname: Lee fullname: Lee, Chang Won – sequence: 31 givenname: Duk Kyu surname: Kim fullname: Kim, Duk Kyu – sequence: 32 givenname: Sang Wook surname: Kim fullname: Kim, Sang Wook – sequence: 33 givenname: Chung Gu surname: Cho fullname: Cho, Chung Gu – sequence: 34 givenname: Jung Han surname: Kim fullname: Kim, Jung Han – sequence: 35 givenname: Yeo-Joo surname: Kim fullname: Kim, Yeo-Joo – sequence: 36 givenname: Jae-Myung surname: Yoo fullname: Yoo, Jae-Myung – sequence: 37 givenname: Kyung Wan surname: Min fullname: Min, Kyung Wan – sequence: 38 givenname: Moon-Kyu orcidid: 0000-0002-8728-7184 surname: Lee fullname: Lee, Moon-Kyu |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38763510$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART003103626$$DAccess content in National Research Foundation of Korea (NRF) |
| BookMark | eNp1kl1v0zAUhiM0xEbZJbfIEjcDKcVfiRNuUGkLVNo0NMq15Tj25i6xi-0UlX_JP8Jtx8Qm4RsfHz_n9bH9Ps-OrLMqy14iOKawJu_afjXGEJMxhIw9yU4wJiQvYcWO7mNWH2enIaxgGrRKWP0sOyYVK0mB4En2e661kUJugbAt-Ca0ilvgNLhQUTvfG7vPT6LzGxGiiCkxdX1jbAqdBcsb5cV6CzZhDC6cdfFu_dPEGzA3uyWY-eEapLrldq0ABjMjGhVVSEd0nYlD2J8w24bOrE2reiPA1ySubAzgbLK8vFhM37wHMzc0nco_dsa2qgVXqcb15lcKp85G77ouhUtvRPcie6pFF9Tp3TzKvn-aL6df8vPLz4vp5DyXlLKYUyQIkVqVVEtWNkKimrZVATGTUCApSqE1baXCCDJaUoxLgUuiCsUqIWtSklH29qBrvea30nAnzH6-dvzW88nVcsERLIoaMZrgxQFunVjxtTe98Nt9xT7h_DUXPhrZKU4Y1gVtipZVlNaaCVZVUtOiRFo0kMKk9eGgtR6aXqUW0_1F90D04Y41N6mpDUeIQIaSL0bZ2Z2Cdz8GFSLvTZDpO4RVbgicwIJBRkhdJfT1I3TlBm_Tw3KCUYUKTBI4yl7929J9L399loD8AEjvQvBK3yMI8p2VebIy31mZ76ycePKIlybuLZduZLr_VP0BHML4Zg |
| CitedBy_id | crossref_primary_10_4239_wjd_v16_i4_100533 crossref_primary_10_1080_14740338_2024_2424438 |
| Cites_doi | 10.2337/diacare.17.10.1093 10.1186/1475-2840-5-20 10.1016/j.diabres.2019.107843 10.1016/j.diabres.2009.10.007 10.1007/s00125-008-1053-5 10.1038/nm.3787 10.1007/s00125-014-3374-x 10.1253/circj.cj-14-0810 10.5551/jat.rv16004 10.1136/bmjopen-2014-007280 10.1016/s0140-6736(10)61350-5 10.1038/s41598-020-71908-9 10.1136/bmjgast-2015-000075 10.1186/s12933-016-0486-2 10.4093/dmj.2020.0254 10.1016/j.ijcard.2016.10.015 10.1111/dom.13491 |
| ContentType | Journal Article |
| Copyright | 2024. This work is licensed under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Copyright © 2024 Korean Diabetes Association 2024 |
| Copyright_xml | – notice: 2024. This work is licensed under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Copyright © 2024 Korean Diabetes Association 2024 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA ACYCR |
| DOI | 10.4093/dmj.2023.0077 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Proquest Central ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni) Medical Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals Korean Citation Index |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 2233-6087 |
| EndPage | 739 |
| ExternalDocumentID | oai_kci_go_kr_ARTI_10559174 oai_doaj_org_article_372f54b5d78449f7a788cf4561fab040 PMC11307122 38763510 10_4093_dmj_2023_0077 |
| Genre | Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Journal Article |
| GrantInformation_xml | – fundername: Daewoong Pharmaceutical Company – fundername: HK inno.N Corp. |
| GroupedDBID | 5-W 5VS 7RV 7X7 88E 8FI 8FJ 8JR 8XY 9ZL AAYXX ABDBF ABUWG ADBBV AFKRA ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV BENPR CCPQU CITATION DIK EF. FYUFA GROUPED_DOAJ HMCUK HYE KQ8 M1P M48 NAPCQ O5R O5S PGMZT PHGZM PHGZT PIMPY PSQYO RPM UKHRP ADRAZ CGR CUY CVF ECM EIF IPNFZ NPM RIG 3V. 7XB 8FK AZQEC DWQXO K9. PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM ACYCR OK1 |
| ID | FETCH-LOGICAL-c447t-41a33cfe64fc76bac194d85027c0a1ca6aff4dce2107464226a263e5e78ac9363 |
| IEDL.DBID | M48 |
| ISSN | 2233-6079 2233-6087 |
| IngestDate | Thu Jan 09 03:21:57 EST 2025 Wed Aug 27 01:25:06 EDT 2025 Thu Aug 21 18:31:52 EDT 2025 Thu Sep 04 16:36:09 EDT 2025 Fri Jul 25 09:20:08 EDT 2025 Thu Apr 03 07:08:32 EDT 2025 Thu Apr 24 22:59:22 EDT 2025 Tue Jul 01 03:40:12 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | Atorvastatin Metformin Dyslipidemias Diabetes mellitus |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c447t-41a33cfe64fc76bac194d85027c0a1ca6aff4dce2107464226a263e5e78ac9363 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 https://e-dmj.org/journal/view.php?number=2847 |
| ORCID | 0000-0002-1039-5769 0000-0002-8728-7184 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.4093/dmj.2023.0077 |
| PMID | 38763510 |
| PQID | 3218152373 |
| PQPubID | 7191758 |
| PageCount | 10 |
| ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_10559174 doaj_primary_oai_doaj_org_article_372f54b5d78449f7a788cf4561fab040 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11307122 proquest_miscellaneous_3057073398 proquest_journals_3218152373 pubmed_primary_38763510 crossref_primary_10_4093_dmj_2023_0077 crossref_citationtrail_10_4093_dmj_2023_0077 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-07-01 |
| PublicationDateYYYYMMDD | 2024-07-01 |
| PublicationDate_xml | – month: 07 year: 2024 text: 2024-07-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Korea (South) |
| PublicationPlace_xml | – name: Korea (South) – name: Sŏul |
| PublicationTitle | Diabetes & metabolism journal |
| PublicationTitleAlternate | Diabetes Metab J |
| PublicationYear | 2024 |
| Publisher | Korean Diabetes Association / Daehan Dangnyobyeong Hakoe Korean Diabetes Association 대한당뇨병학회 |
| Publisher_xml | – name: Korean Diabetes Association / Daehan Dangnyobyeong Hakoe – name: Korean Diabetes Association – name: 대한당뇨병학회 |
| References | ref13 ref12 ref15 ref14 ref20 ref11 ref2 ref1 ref17 ref16 ref19 Eliasson (ref4) 2011 ref18 ref8 ref7 Xu (ref10) 2015 ref9 ref3 ref6 McEwen (ref5) 2012 |
| References_xml | – ident: ref12 doi: 10.2337/diacare.17.10.1093 – ident: ref7 doi: 10.1186/1475-2840-5-20 – ident: ref2 doi: 10.1016/j.diabres.2019.107843 – ident: ref3 doi: 10.1016/j.diabres.2009.10.007 – ident: ref11 doi: 10.1007/s00125-008-1053-5 – ident: ref13 doi: 10.1038/nm.3787 – ident: ref14 doi: 10.1007/s00125-014-3374-x – ident: ref17 doi: 10.1253/circj.cj-14-0810 – ident: ref8 doi: 10.5551/jat.rv16004 – ident: ref19 doi: 10.1136/bmjopen-2014-007280 – start-page: 2095 volume-title: Clinical usefulness of different lipid measures for prediction of coronary heart disease in type 2 diabetes: a report from the Swedish National Diabetes Register year: 2011 ident: ref4 – ident: ref15 doi: 10.1016/s0140-6736(10)61350-5 – start-page: 1858 volume-title: Effects of metformin on metabolite profiles and LDL cholesterol in patients with type 2 diabetes year: 2015 ident: ref10 – ident: ref1 doi: 10.1038/s41598-020-71908-9 – ident: ref18 doi: 10.1136/bmjgast-2015-000075 – ident: ref20 doi: 10.1186/s12933-016-0486-2 – ident: ref9 doi: 10.4093/dmj.2020.0254 – ident: ref6 doi: 10.1016/j.ijcard.2016.10.015 – start-page: 1301 volume-title: Predictors of mortality over 8 years in type 2 diabetic patients: Translating Research Into Action for Diabetes (TRIAD) year: 2012 ident: ref5 – ident: ref16 doi: 10.1111/dom.13491 |
| SSID | ssj0000480779 |
| Score | 2.334364 |
| Snippet | Background: It is well known that a large number of patients with diabetes also have dyslipidemia, which significantly increases the risk of cardiovascular... It is well known that a large number of patients with diabetes also have dyslipidemia, which significantly increases the risk of cardiovascular disease (CVD).... Background It is well known that a large number of patients with diabetes also have dyslipidemia, which significantly increases the risk of cardiovascular... |
| SourceID | nrf doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 730 |
| SubjectTerms | Adult Aged Analysis of covariance atorvastatin Atorvastatin - administration & dosage Atorvastatin - therapeutic use Chi-square test Cholesterol, LDL - blood Clinical trials Combination therapy Diabetes diabetes mellitus Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Double-Blind Method Drug dosages Drug Therapy, Combination dyslipidemias Dyslipidemias - blood Dyslipidemias - drug therapy Ethics Female Glucose Glycated Hemoglobin - analysis Humans Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - therapeutic use Kruskal-Wallis test Lipids Male Metabolic disorders metformin Metformin - administration & dosage Metformin - therapeutic use Middle Aged Mortality Original Patients Public health Treatment Outcome Variance analysis 내과학 |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3fb9MwELbQHiZeEIxfHQMZgRBIZGtix05467ZOA6kIQSftzbIde5R1KUrTSeW_5D_izs6qFoF44alWYiuO7-y7r7n7jpCX3LPcZ4VIitzahOfWJLoqodU3wvS9scJiNvLoozg94x_O8_O1Ul8YExbpgePCHTCZ-ZybvJIF56WXGjCb9Wj2vTaggXj6gs1bA1PhDMZM6UC0B-aPJaIvy0iwCXCGHVRX3_axbDjyZssNgxR4-8HM1I3_k8v5e-Tkmik6uUvudD4kHcS53yO3XL1DtkfdV_L75OcQeSG0XVJdV_SL9q5d0pmnI9eiizqpw_UBoO1rjQlFcAGOBYDIQUp0HIkG6PV8n8KW71K0lhT_sqVDzOFo6HGzuKAwDmEszWgXVzOHR0zBr1_MwxOOl-DExgq0mn6KBK5z-nowxsqJb95RcN7N1CWHU6RsrOhnGDO7mvyA5lEMoJ9Cc4w75AE5OxmOj06TrnRDYjmXbcJTzZj1TnBvpTDapiWvihwwsO3r1GqhveewihnGgwrM5tWZYC53stC2ZII9JFv1rHaPCQX_QWhnTG4RShaydHBsmKwCnFNg_d4eeXsjP2U7XnMsrzFVgG9Q3ArErVDcCsXdI69W3b9HQo-_dTxEZVh1Qh7ucAG0U3Xaqf6lnT3yAlRJXdpJGI-_FzN12ShAK-8VFicFuAyvsHejaqo7QuaKofOVZ0yyHnm-ug2bH7_o6NrNFtAHvG2sulkWPfIoauZqvixwDaYwhWJDZzdeaPNOPfkaCMZTcGxkmmW7_2MJnpDbsKY8hjjvka22Wbin4Mi15lnYs78AJZFFqA priority: 102 providerName: Directory of Open Access Journals – databaseName: Proquest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Rb9MwELagkxASQjBgFAYyAiGQyNbEju3wgtqt00DaNI1O2ptlO3Ep65KRtJPKv-QfcZekhSLgKVZiK07OPt9n331HyCvuWewjJQIVOxfw2NnApAmUelbYnrdOOIxGPjoWh2f803l83m64Va1b5VIn1oo6LRzuke8yXIsANUn24epbgFmj8HS1TaFxk2yAClZxh2wMhscnp6tdljpiuibcg2WQBaInk4ZoE2AN200vv-5g-nDkz5ZrC1PN3w_LTV76v5mef3pQ_rYkHdwjd1tbkvYb4d8nN7J8k9w6ak_LN8mdZk-ONqFGD8iPIfJFGLegJk_pZ-Oz2YIWnh5lMzRdJ3l9vw8o_NpgoBHcAHUB0LmWHh01BAT0utqhoAra0K0Fxa1cOsTYjpLul_MxhXYIb2lEW3-bCl4xBXt_XtVv2F-AcdtkpjX0pCF2reib_ggzKr59T8Got9MsGEyRyjGlp9CmuJx8h-Je41g_heIIZ85DcnYwHO0dBm1Kh8BxLmcBDw1jzmeCeyeFNS5MeKpiwMauZ0JnhPGew1-N0E9UYJSviQTL4kwq4xIm2CPSyYs8e0wo2BXCZNbGDiGmkkkG6sRGKeAfhXl9u-TdUp7atXznmHZjqgH3oPg1iF-j-DWKv0ter6pfNUQf_6o4wMGxqoT83PWNohzrdrprJiMfcxunUnGeeGmkUs6jseqNBb3ZJS9haOkLN6nb43Vc6ItSA4r5qDFpKcBo-ITt5dDTrWqp9K-J0CUvVo9BKeBJj8mzYg51wArHbJyJ6pKtZqSu-stqDsIQuqDWxvDaB60_ySdfauLxEAweGUbRk__36ym5DX-LN07N26QzK-fZMzDdZvZ5Oz9_AvxSQ_w priority: 102 providerName: ProQuest |
| Title | Efficacy and Safety of Metformin and Atorvastatin Combination Therapy vs. Monotherapy with Either Drug in Type 2 Diabetes Mellitus and Dyslipidemia Patients (ATOMIC): Double-Blinded Randomized Controlled Trial |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38763510 https://www.proquest.com/docview/3218152373 https://www.proquest.com/docview/3057073398 https://pubmed.ncbi.nlm.nih.gov/PMC11307122 https://doaj.org/article/372f54b5d78449f7a788cf4561fab040 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART003103626 |
| Volume | 48 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Diabetes and Metabolism Journal, 2024, 48(4), 204, pp.730-739 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3fb9MwELbYJiFeEL8pjMoIhEAipYkdO-EFtVunAeo0Rif1zbKduJRlCaTtRPkv-Y-4S9JCYUi8tJFjJ47vfP4u8X1HyFPuWOiCSHhRaK3HQ2s8ncRw1DXCdJ2xwmI08vBIHJ7yd-Nw_ItSqBnA2aWuHeaTOi2zzrevyzcw4QG_dsA7Ya-S888dzAKONNhyi-zAoiRQwYcN0q-MMoZOV8x7sB4yT3RlXDNu_n2FjRWqIvKHdScv3WUY9M-tlL-tTQc3yPUGVNJerQU3yZU0v0WuDpvP5rfJjwESRWi7pDpP6Eft0vmSFo4O0zli1mlelffA_b7QGGEEBWAnwGeuxEZHNfMAvZh1KNiAJmZrSfEdLh1gUEdJ98vFhEI79GtpQJuNNjO4RQZAfzGr7rC_BFRbp6TV9LhmdJ3R570RplJ88ZoCmjdZ6vUz5HBM6Am0Kc6n3-Fwr95Rn8HhCKfMHXJ6MBjtHXpNLgfPci7nHvc1Y9algjsrhdHWj3kSheAU2672rRbaOQ6jGOAGUYHhvToQLA1TGWkbM8Huku28yNP7hAKgEDo1JrToW0YyTsGOmCABxyfChL4t8nIlP2UbonPMt5EpcHhQ3ArErVDcCsXdIs_W1b_UDB__qthHZVhXQmLuqqAoJ6qZ54rJwIXchImMOI-d1DKKrEOU6rQBg9kiT0CV1JmdVu3xf1Kos1KB-_JWYbZS8J_hEXZXqqZWU0IxRGNhwCRrkcfr02AN8BOPztNiAXUAfmMazjhqkXu1Zq77yyryQR-6EG3o7MYDbZ7Jp58qxnEfkI70g-DBf_X-IbkGg8brTc27ZHteLtJHAN3mpk225Fi2yU5_cHR80q5egMDv-w9Ru5quPwFznUcF |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1tb9MwELbGkAAJIRhvhQFGvAgksrWxEydICHVrp5Wt0wSd1G_GcexS1iUjbYfKj-K_8I-4c9JCEfBtn2olduPkzud7bN9zhDzllgXWj0IvCrT2eKATT6UxlOpJmNRtokON0cjdg3D3iL_rB_0V8n0eC4PHKuc20RnqNNe4Rr7JcC4C1CTY29MvHmaNwt3VeQqNUi32zOwrQLbxm04L5PvM93fave1dr8oq4GnOxcTjDcWYtibkVoswURpgfBoFAM90XTW0CpW1PNXGx6OKIQaaKj9kJjAiUjpmIYP_vUAuwsRbR65-0ReLNR0Xn-3o_WDSZV5YF3FJ6wkgim2mJ583MFk5snWLpWnQZQuAyS0r7N8c3T_Pa_42Ae5cJ9cqz5U2S1W7QVZMtkYudau9-TVytVwBpGVg003yo43sFErPqMpS-kFZM5nR3NKumaCjPMzc9SZg_jOFYU1wAYwTAHWnK7RX0h3Qs_EGBcNTBYrNKC4c0zZGkhS0VUwHFNohmKY-rU73jOERI0AX07F7QmsGrnSZB1fRw5JGdkxfNHuYv_HlawoQIhkZb2uExJEpfQ9t8pPhNyhul8f4R1Ds4Ti9RY7ORdS3yWqWZ-YuoeDFhMokSaAR0EYiNmC8Ej8FtBVhFuEaeTWXp9QVuzom-RhJQFkofgnilyh-ieKvkeeL6qclrci_Km6hciwqIRu4u5AXA1kZF8mEbwOeBKmIOI-tUCKKtEXX2KoErHSNPAHVksd66Nrj7yCXx4UEzNSRmCIVQDu8wvpc9WRlyMby17CrkceL22CCcF9JZSafQh3w-TH3ZxzVyJ1SUxf9ZY7xsAFdiJZ0eOmFlu9kw0-O5rwB7pVo-P69__frEbm82-vuy_3Owd59cgW-HC-PU6-T1UkxNQ_AaZwkD91IpeTjeZuGn6vQf4E |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+and+Safety+of+Metformin+and+Atorvastatin+Combination+Therapy+vs.+Monotherapy+with+Either+Drug+in+Type+2+Diabetes+Mellitus+and+Dyslipidemia+Patients+%28ATOMIC%29%3A+Double-Blinded+Randomized+Controlled+Trial&rft.jtitle=Diabetes+%26+metabolism+journal&rft.au=%EC%9D%B4%EC%A7%80%EC%9D%80&rft.au=%EC%9C%A0%EC%8A%B9%ED%9D%AC&rft.au=%EA%B9%80%EC%84%B1%EB%9E%98&rft.au=%EC%95%88%EA%B7%9C%EC%A0%95&rft.date=2024-07-01&rft.pub=%EB%8C%80%ED%95%9C%EB%8B%B9%EB%87%A8%EB%B3%91%ED%95%99%ED%9A%8C&rft.issn=2233-6079&rft.eissn=2233-6087&rft.spage=730&rft.epage=739&rft_id=info:doi/10.4093%2Fdmj.2023.0077&rft.externalDBID=n%2Fa&rft.externalDocID=oai_kci_go_kr_ARTI_10559174 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2233-6079&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2233-6079&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2233-6079&client=summon |